Cannabis Industry Is About Money, Not Medicine (Opinion)
Last Updated: Wednesday June 12, 2024
(The Washington Times) The Biden Administration’s recent move to reschedule marijuana from Schedule I to Schedule III has been drawing criticism from activists on both sides of the issue.
For those focused on science and medical efficacy, it’s a move that fails to recognize the growing body of scientific and medical data that shows today’s marijuana is more addictive and more harmful than that of previous generations. For pro-pot activists, the move comes up short of fully legalizing their wonder drug. It also does nothing to deal with criminal justice reform.
The move, however, has a clear winner: the cannabis industry. Companies such as Trulieve, Cresco, Canopy Growth and Cronos and their allies Big Tobacco and Wall Street will all see a boon from President Biden’s election-year “reform.”